Utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab

Aim Cetuximab is an anti‐epidermal growth factor receptor antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSRs) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti‐cetuximab immunoglobulin E...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology Vol. 83; no. 3; pp. 623 - 631
Main Authors: Dupont, Benoît, Mariotte, Delphine, Dugué, Audrey E., Clarisse, Bénédicte, Grellard, Jean‐Michel, Babin, Emmanuel, Chauffert, Bruno, Dakpé, Stéphanie, Moldovan, Cristian, Bouhier‐Leporrier, Karine, Reimund, Jean‐Marie, Di Fiore, Frederic, Zanetta, Sylvie, Mailliez, Audrey, Do, Pascal, Peytier, Annie, Galais, Marie‐Pierre, Florescu, Carmen, Schott, Roland, Le Mauff, Brigitte, Gervais, Radj
Format: Journal Article
Language:English
Published: England Wiley 01.03.2017
John Wiley and Sons Inc
Subjects:
anaphylaxis
anti‐immunoglobulin E antibodies
cetuximab
Cetuximab - immunology
Drug Hypersensitivity - blood
Drug Hypersensitivity - epidemiology
Drug Hypersensitivity - immunology
Drug Safety
Female
France - epidemiology
Humans
hypersensitivity
Immunoglobulin E - blood
Life Sciences
Male
Middle Aged
Prospective Studies
Risk Factors
cetuximab
anaphylaxis
hypersensitivity
anti-immunoglobulin E antibodies
ISSN:0306-5251, 1365-2125, 1365-2125
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Cetuximab is an anti‐epidermal growth factor receptor antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSRs) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti‐cetuximab immunoglobulin E (IgE) detection in order to identify patients at risk of HSR to cetuximab. Methods We included patients ready to receive a first cetuximab infusion in a prospective cohort carried out at nine French centres. Pretreatment anti‐cetuximab IgE levels were measured. We compared the proportion of severe HSRs in the low anti‐cetuximab IgE levels (≤29 IgE arbitrary units) subgroup with that in a historical cohort of 213 patients extracted from a previous study. Results Of the 301 assessable patients (mean age: 60.9 ± 9.3 years, head‐and‐neck cancer: 77%), 66 patients (22%) had high anti‐cetuximab IgE levels, and 247 patients received cetuximab (including 38 with high anti‐cetuximab levels). Severe HSRs occurred in eight patients (five grade 3 and three grade 4). The proportion of severe HSRs was lower in the low anti‐cetuximab IgE levels subgroup vs. the historical cohort (3/209 [1.4%] vs. 11/213 [5.2%], odds ratio, 0.27, 95% confidence interval, 0.07–0.97), and higher in high vs. low anti‐cetuximab IgE levels subgroup (5/38 [13.2%] vs. 3/209 [1.4%]; odds ratio, 10.4, 95% confidence interval, 2.4–45.6). Patients with severe HSRs had higher anti‐cetuximab IgE levels than patients without reaction (median, 45 vs. 2 IgE arbitrary units, P = 0.006). Conclusions Detection of pretreatment anti‐cetuximab IgE is feasible and helpful to identify patients at risk of severe cetuximab‐induced HSRs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC5306475
ISSN:0306-5251
1365-2125
1365-2125
DOI:10.1111/bcp.13140